Price T Rowe Associates Inc Gritstone Bio, Inc. Transaction History

Price T Rowe Associates Inc

$816 Billion
Q1 2024

A detailed history of Price T Rowe Associates Inc transactions in Gritstone Bio, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 86,827 shares of GRTS stock, worth $50,359. This represents 0.0% of its overall portfolio holdings.

Number of Shares

86,827

Previous 83,489 4.0%

Holding current value

$50,359

Previous $171,000 30.99%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$1.96 - $2.9 $6,542 - $9,680	3,338 Added 4.0%	86,827 $224,000
Q4 2023 Feb 14, 2024	BUY	$1.28 - $2.85 $3,781 - $8,418	2,954 Added 3.67%	83,489 $171,000
Q3 2023 Nov 14, 2023	BUY	$1.19 - $2.26 $18,802 - $35,708	15,800 Added 24.41%	80,535 $139,000
Q2 2023 Aug 14, 2023	BUY	$1.66 - $3.03 $29,606 - $54,040	17,835 Added 38.03%	64,735 $127,000
Q1 2023 May 15, 2023	BUY	$2.13 - $3.74 $20,448 - $35,904	9,600 Added 25.74%	46,900 $131,000

Q2 2022 Aug 15, 2022	SELL	$1.77 - $4.34 $6,724 - $16,487	-3,799 Reduced 9.24%	37,300 $90,000
Q1 2022 May 16, 2022	BUY	$4.03 - $12.19 $48,936 - $148,023	12,143 Added 41.94%	41,099 $169,000
Q4 2021 Feb 14, 2022	SELL	$8.76 - $13.71 $19,166 - $29,997	-2,188 Reduced 7.03%	28,956 $372,000
Q3 2021 Nov 15, 2021	SELL	$6.41 - $13.54 $1.11 Million - $2.34 Million	-172,726 Reduced 84.72%	31,144 $336,000
Q2 2021 Aug 16, 2021	SELL	$8.13 - $10.2 $874,991 - $1.1 Million	-107,625 Reduced 34.55%	203,870 $1.86 Million
Q1 2021 May 17, 2021	BUY	$4.07 - $27.11 $1.27 Million - $8.44 Million	311,495 New	311,495 $2.94 Million

Others Institutions Holding GRTS

# of Institutions

Shares Held

45.6M

Call Options Held

861K

Put Options Held

4.52M

View Full List

About Gritstone bio, Inc.

Ticker GRTS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 73,006,896
Market Cap $42.3M
Description
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder ...

More about GRTS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.

Account

Price T Rowe Associates Inc Gritstone Bio, Inc. Transaction History